BofA raised the firm’s price target on Alkermes (ALKS) to $35 from $34 and keeps a Neutral rating on the shares. The firm’s higher target ...

整体上，通过氨基酸残基间的相互作用，多肽形成了特定的三维结构以识别并结合 OX2 受体。 作用机理及研究进展 作用机理：(Ala11,D-Leu15)-Orexin B 是一种高效且选择性的 OX2 受体激动剂，对 OX2 受体的选择性比对 OX1 受体高 400 倍 。当它与 OX2 受体结合后，会诱导 ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

For most of us, getting less than seven hours of sleep translates into grogginess, sluggish thinking, and an overwhelming urge to crawl back into bed. But some people wake up fresh and energized after ...

RBC Capital initiated coverage of Alkermes (ALKS) with a Sector Perform rating and $40 price target The company’s next-generation orexin has a ...

Analysts have recently evaluated Harmony Biosciences Hldgs and provided 12-month price targets. The average target is $58.0, ...

Dr Leah Kaylor, a psychologist and sleep expert says: “Occasionally, more sleep may be required after emotionally intense ...

该公司的分析表明，Alkermes的股价目前已经考虑了即期挑战，同时也计入了其开发中治疗药物的潜在收入。RBC Capital Markets的立场表明，他们正在密切关注更多数据，以进一步评估该药物在竞争市场中的前景以及公司的整体财务健康状况。 InvestingPro ...

The two major types of narcolepsy are: Narcolepsy type 1. People with type 1 narcolepsy have low levels of orexin (hypocretin), a brain chemical that regulates wakefulness. Damage to the brain ...